EGFR and neoplasm: By elucidating the adaptation mechanism following the initial treatment with EGFR-TKIs, we could develop novel initiation therapies to eradicate tumor cells, and thereby further improve the outcome of advanced EGFR-mutated NSCLC by preventing the development of acquired resistance.